Trials / Completed
CompletedNCT01699659
The Efficacy & Safety of the UAS Immunotherapy Protocol
The Efficacy and Safety of the United Allergy Service (UAS) Immunotherapy Protocol
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (actual)
- Sponsor
- United Allergy Services · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.
Detailed description
Patients will be assessed for efficacy of the immunotherapy protocol by completing Consented-IRB approved clinical, medication, quality of life survey questions comparing current status while on therapy in contrast to 12 months before the inception of therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | allergen immunotherapy | allergy shots |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2012-10-04
- Last updated
- 2012-10-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01699659. Inclusion in this directory is not an endorsement.